We are a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our pharmaceutical collaborators – a novel product pipeline of ion channel modulators to address therapeutic areas of high unmet medical need, such as pain and epilepsy.
Shutting Down Pain
Xenon featured in Genentech’s Big Ideas animated short
May 9, 2017 – Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
May 4, 2017 – Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2017 Financial Results and Provide Corporate Update
April 27, 2017 – Xenon Pharmaceuticals to Present at the 2017 Bloom Burton & Co. Healthcare Investor Conference
April 26, 2017 – Xenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy